Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2022 | Unmet needs and future questions in cellular therapy for myeloma

Adam Cohen • 26 Aug 2022
IMS 2022
Multiple Myeloma CAR-T

Adam Cohen, MD, University of Pennsylvania, Philadelphia, PA, highlights key unmet needs in cellular therapy for multiple myeloma, including the need to improve manufacturing processes and patient responses, as well as better mitigate toxicities associated with CAR-T products. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

More from Adam Cohen

Latest advances in T-cell engaging therapies for multiple myeloma
Adam Cohen et al. • 15 Apr 2023
1:45
CARTITUDE-2 update: cilta-cel in relapsed and lenalidomide-refractory patients with multiple myeloma
Adam Cohen • 26 Aug 2022
2:01
An update on cohort C from the CARTITUDE-2 trial
Adam Cohen • 26 Aug 2022
3:15
CARTITUDE update: Patient expectations and experiences of cilta-cel in R/R myeloma
Adam Cohen • 10 Dec 2020

Related Videos

1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
3:23
Molecular characteristics associated with increased risk of disease progression in SMM
Mark Bustoros • 27 Sep 2023
The content of VJHemOnc is intended for healthcare professionals